Education
About Us
Working with TipRanks
Follow Us
Alkermes plc (ALKS)
:ALKS
ALKS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$25.17 - $36.45
Previous CloseN/A
Volume176.14K
Average Volume (3M)1.76M
Market Cap
$4.38B
Enterprise Value$3.87B
Total Cash (Recent Filing)$399.81M
Total Debt (Recent Filing)$74.10M
Price to Earnings (P/E)12.7
Beta0.80
Next Earnings
Oct 22, 2025EPS Estimate
0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.67
Shares Outstanding165,077,970
10 Day Avg. Volume2,688,594
30 Day Avg. Volume1,763,102
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.88
Enterprise Value/Revenue2.56
Enterprise Value/Gross Profit2.92
Enterprise Value/Ebitda8.65
Forecast
1Y Price Target
$40.26Price Target Upside46.99% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
Bulls Say, Bears Say
Bulls Say
Market ConfidenceThe stock has bounced back approximately 10% to around its pre-readout levels due to continued confidence and a rebound in the broader biopharma market.
Safety ProfileImportantly, there were no new safety signals in the OLE in patients who titrated up from 6 mg to 8 mg, which is positive and point to improved safety.
Bears Say
Competitive LandscapeThe narcolepsy treatment category is crowded, with new data from other companies expected soon, which impacts competitive positioning.
Visual DisturbancesThere are lingering concerns regarding visual disturbances as a potential adverse effect, which the company did not address in the limited release.
Alkermes News
ALKS FAQ
What was Alkermes plc’s price range in the past 12 months?
Alkermes plc lowest stock price was $25.16 and its highest was $36.45 in the past 12 months.
What is Alkermes plc’s market cap?
Alkermes plc’s market cap is $4.38B.
When is Alkermes plc’s upcoming earnings report date?
Alkermes plc’s upcoming earnings report date is Oct 22, 2025 which is in 34 days.
How were Alkermes plc’s earnings last quarter?
Alkermes plc released its earnings results on Jul 29, 2025. The company reported $0.668 earnings per share for the quarter, beating the consensus estimate of $0.356 by $0.312.
Is Alkermes plc overvalued?
According to Wall Street analysts Alkermes plc’s price is currently Undervalued.
Does Alkermes plc pay dividends?
Alkermes plc does not currently pay dividends.
What is Alkermes plc’s EPS estimate?
Alkermes plc’s EPS estimate is 0.4.
How many shares outstanding does Alkermes plc have?
Alkermes plc has 165,077,970 shares outstanding.
What happened to Alkermes plc’s price movement after its last earnings report?
Alkermes plc reported an EPS of $0.668 in its last earnings report, beating expectations of $0.356. Following the earnings report the stock price went up 3.25%.
Which hedge fund is a major shareholder of Alkermes plc?
Currently, no hedge funds are holding shares in ALKS
Alkermes Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$40.26 (46.99% Upside)
$40.26 (46.99% Upside)
Blogger Sentiment
Bullish
ALKS Sentiment 70%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 1.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.9%
Last 30 Days ▲ 6.0%
Last 30 Days ▲ 6.0%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-1.58%
12-Months-Change
Fundamentals
Return on Equity
23.94%
Trailing 12-Months
Asset Growth
2.08%
Trailing 12-Months
Company Description
Alkermes plc
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
ALKS Company Deck
ALKS Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive outlook for Alkermes, with strong financial results, successful clinical trial outcomes, and a robust cash position. However, increased R&D expenses and variability in cataplexy endpoint results present challenges.View all ALKS earnings summariesALKS Revenue Breakdown
89.69% U.S.
10.24% Rest of world
0.07% Ireland
ALKS Stock 12 Month Forecast
Average Price Target
$40.26
▲(46.99% Upside)
Technical Analysis
Ownership Overview
1.41% Insiders
30.95% Mutual Funds
25.10% Other Institutional Investors
12.20% Public Companies and
Individual Investors